Coherus BioSciences Stock Price and Value Analysis

Should you buy Coherus BioSciences stock? (NasdaqGM:CHRS). Let's see how it does in our automated value investing analysis system.

  • This company is solid.
  • This company has wild ups and downs.
  • This stock looks overpriced.
  • This company is not making money.
  • This company pays no dividend.

Inside the CHRS Numbers

CHRS Price
(Coherus BioSciences stock price per share)
[?] PE Ratio versus Sector 77% lower than other Healthcare stocks
[?] PE Ratio versus Industry 92% lower than other Biotechnology stocks
[?] Cash Yield -19.14%
[?] Free Cash Flow Jitter 98%

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 9,293,215 shares shorted. With 69,033,425 shares available for purchase and an average trading volume over the past 10 trading days of 825,500, it would take at least 11.258 days for all of the short holders to cover their shorts.

What does this mean to you? At this volume, it'll take more than two trading weeks for shorts to cover. This may indicate a short squeeze play would work! If this stock has good fundamentals and it'll take a while for the short holders to cover, buying now could net you bigger short-term technical gains if and as the price rises.

Is Coherus BioSciences Stock on Sale?

Based on our analysis, we believe that you should not buy Coherus BioSciences right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy CHRS Stock?

Does Coherus BioSciences have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.